Primary Care
Novartis is focused on improving the lives of the hundreds of millions of people with metabolic diseases and provides therapies and support programs to treat diabetes.
The portfolio includes:
- Galvus (vildagliptin)
- Eucreas (vildagliptin and metformin)
